ClinicalTrials.Veeva

Menu

A Comparative Clinical and Radiographic Study of Collagen Based Pulpotomy Versus Biodentine Pulpotomy in Children With Cariously Exposed Vital Primary Molars

Cairo University (CU) logo

Cairo University (CU)

Status and phase

Not yet enrolling
Early Phase 1

Conditions

Carious Exposure of Pulp

Treatments

Drug: sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India
Drug: Biodentine (Septodont, Saint-Maur-des-Fossés, France)

Study type

Interventional

Funder types

Other

Identifiers

NCT05479877
19071991

Details and patient eligibility

About

Pulpotomy of vital primary molars is indicated when caries removal results in pulp exposure. Treatment approaches consist of devitalization using formocresol, preservation using ferric sulfate and regeneration of the remaining pulp tissue using mineral trioxide aggregate and recently Biodentine have been utilized.

The ideal pulpotomy medicament would be biocompatible and bactericidal, in addition, to promoting the healing of the root pulp and be compatible with the physiological process of root resorption.

Searching for more pulpotomy agents, Collagen, a protein that's present abundantly in humans, is an important component of connective tissues and performs multiple functions including wound healing.

Enamel and dentin contain Collagen as one of the components in their organic ground matrix.

Collagen has been used widely in dentistry in periodontal and implant therapy as scaffold for preventing the migration of epithelial cells and encouraging wound repopulation by cells with high regenerative potential.

The Collagen available for dental implication is already sterilized and also reinforced with antibiotic particles to efficiently aid in regeneration and repair without any contamination. The collagen particles

Full description

Pulpotomy is considered the gold standard procedure for treating cariously exposed pulps in asymptomatic primary teeth. Which is based on the healing ability of the radicular pulp tissue following amputation of the infected coronal pulp.

Mineral trioxide aggregate (MTA) has been recommended as the gold standard for vital pulp therapy; however, it has some disadvantages, such as long setting time, poor handling properties, high cost, and the potential for tooth discoloration. Biodentine (Septodont, Saint-Maur-des-Fossés, France), one of the new-generation, bioactive endodontic cements, has been claimed to have improved properties over MTA.

Biodentine presents high biocompatibility with the dental pulp, it has high antibacterial effects and antifungal activity, has a shorter setting time than MTA as a result of the calcium chloride in the liquid component of Biodentine. It also has higher flexural strength, compressive strength and modulus of elasticity than MTA.

Consequently, Biodentine can be used as a pulp dressing as well as a base material.

Quest is on for newer pulpal medicaments that are biocompatible and capable of healing the dental pulp by producing reparative dentin and/or dentinal bridge in response to various stimuli and surgical exposure.

Collagen has a proven rate of success in the field of dentistry as guided tissue regeneration, root conditioning, hemostatic, and wound dressing agent. It has inherent properties like low immune response and toxicity, ability to promote cellular growth and attachment, homeostasis, and added advantage of antibiotic incorporation.

Enrollment

40 estimated patients

Sex

All

Ages

4 to 7 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • • Children:

    1. Aged 4 to 7, in good general health and medically free.
    2. Cooperative patients who will comply to follow ups.
    3. Parents provided with written informed consent. • Teeth:
    <!-- -->
    1. Bilaterally Carious vital primary molars with reversible pulpitis.
    2. Restorable teeth with no more than 1/3 of root resorption.

Exclusion criteria

  • • Children:

    1. Children with medical, physical, or mental conditions.
    2. Unable to attend follow up visits. • Teeth:
    <!-- -->
    1. Primary molars with any congenital anomalies.
    2. Previously accessed teeth.
    3. At operative procedure, haemorrhage control is unachievable after pulpotomy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

40 participants in 2 patient groups

(Experimental group) collagen based Pulpotomy
Experimental group
Description:
(sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)
Treatment:
Drug: sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India
(Control group) Biodentine pulpotomy
Active Comparator group
Description:
Biodentine (Septodont, Saint-Maur-des-Fossés, France)
Treatment:
Drug: Biodentine (Septodont, Saint-Maur-des-Fossés, France)

Trial documents
1

Trial contacts and locations

0

Loading...

Central trial contact

Nihal Bayoumi, Msc; Passant Nagi, Lecturer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems